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Abstract
Antibiotic resistance in pathogens requires new targets for developing novel antibacterials. The 
bacterial type III secretion system (T3SS) is an attractive target for developing antibacterials as it 
is essential in the pathogenesis of many Gram-negative bacteria. The T3SS consists of structural 
proteins, effectors and chaperones. Over 20 different structural proteins assemble into a complex 
nanoinjector that punctures a hole on the eukaryotic cell membrane to allow the delivery of 
effectors directly into the host cell cytoplasm. Defects in the assembly and function of the T3SS 
render bacteria non-infective. Two major classes of small molecules, salicylidene acylhydrazides 
and thiazolidinones, have been shown to inhibit multiple genera of bacteria through the T3SS. 
Many additional chemically and structurally diverse classes of small molecule inhibitors of the 
T3SS have been identified as well. While specific targets within the T3SS of a few inhibitors have 
been suggested, the vast majority of specific protein targets within the T3SS remain to be 
identified or characterized. Other T3SS inhibitors include polymers, proteins and polypeptides 
mimics. In addition, T3SS activity is regulated by its interaction with biologically relevant 
molecules, such as bile salts and sterols, which could serve as scaffolds for drug design.
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Introduction
Pathogenic Gram-negative bacteria pose a significant global health impact with an estimated 
2 million infections and 23,000 deaths per year in just the United States (1). Examples of 
these organisms include Pseudomonas, Shigella, Salmonella, Chlamydia, enteropathogenic 
E. coli (EPEC), and Yersinia. The appearance and rapid evolution of multidrug resistant 
strains has become of great concern for public health (2–4). Unfortunately, the development 
of new antibiotics presents a difficult challenge. Since 2009 three antibiotics targeting Gram-
negative bacteria, though not exclusively, have been approved as the deadline approaches for 
the initiative of the Infectious Diseases Society of America’s for at least 10 new antibiotics 
by 2020 (5). The rate of entry of new antibiotics into the pipeline is extremely slow (6–9). 
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This is largely due to several factors, namely, (i) the lack of novel antibiotic targets (10), (ii) 
high throughput screens often turn up known targets or novel targets that do not make it past 
early stages of drug development due to toxicity or off target effects (11), and (iii) the 
disinterest of big pharmaceutical companies to discover new antibiotics or conduct clinical 
trials due the problem of antibiotic resistance and poor investment return has only 
exacerbated the situation (11, 12). The rapid emergence of multidrug resistant strains 
coupled with the dearth of novel antibiotics suggests a need for identifying novel targets for 
development of antibiotics.
Traditional antibiotics often fall into two classes: bactericidal compounds that cause cell 
death and/or bacteriostatic compounds that inhibit cellular growth (11). In either case, these 
drugs often induce a selection pressure on bacteria to develop drug resistance, which is 
usually obtained via horizontal gene transfer between bacteria or by de novo mutations (11). 
Targeting virulence pathways of pathogenic bacteria has been suggested as an alternative 
strategy (13, 14). One current theory is that the use of antivirulence or anti-infective drugs, 
in contrast to antibiotics, will dampen the selection pressure for the emergence of resistant 
strains because these drugs do not directly harm the organism (15, 16). Notably, there have 
been documented cases of resistance to antivirulence drugs, though it has been argued that 
the existence of such mechanisms for resistance does not suggest it will become a problem 
in a clinical setting (15). Another advantage is that because virulence mechanisms are used 
by pathogenic bacteria, antivirulence drugs are hypothesized to have less of an influence on 
the host commensal flora when compared to traditional broad spectrum antibiotics (17).
The Type III Secretion System – Multiple Targeting Opportunities
Overview of the T3SS
The type III secretion system functions as a conduit for delivery of virulence factors by 
translocating proteins from the bacterial cytoplasm into the eukaryotic host cell cytoplasm to 
facilitate infection (18). The structural component of the T3SS, the needle complex, was first 
visualized by Galan & coworkers in 1998 (19) and since then the structures and functions of 
many T3SS proteins have been elucidated [reviewed in (20–23)]. T3SS proteins are highly 
homologous in sequence, structure and function among different bacteria (20, 24, 25). 
Therefore, protein-protein interactions within the system among different bacteria and with 
host cells are thought to occur through similar mechanisms. This theory is supported by the 
similarities observed between the assembly of the Salmonella and Shigella T3SS needles 
(26) and conserved structural motifs within the basal structure (27). Importantly, disruption 
of many aspects of the T3SS often abolishes pathogenicity. For these reasons, the potential 
of using the T3SS as a pseudo-broad spectrum antivirulence target is of great interest (13). 
As the T3SS is complex, there are many different potential targeting strategies relating to 
various aspects of the system, which are outlined in Figure 1 and described below.
The T3SS needle apparatus
The T3SS needle apparatus is made up of around 25 different proteins that assemble 
together to regulate and facilitate the secretion of effector proteins into host cells (21). 
Together, the membrane-embedded export apparatus controls the secretion of proteins and 
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anchors the apparatus into the bacterial membrane (28). An ATPase provides recognition for 
chaperone/effector complexes and is thought to provide energy for insertion and unfolding 
of effector proteins into the apparatus (29). The needle provides a ~25Å diameter 
extracellular channel for the secretion of partially unfolded effector proteins (26, 28). The tip 
complex regulates secretion and is a scaffold for translocon assembly (30). Finally, the 
translocon creates a pore in host cell membrane (31). Many subsections of the apparatus, 
such as the tip, needle, inner ring and outer ring, are assembled by oligomers of a single 
protein whose affinities are governed by the sum of weak protein-protein interactions (32). 
Furthermore, the structures of many T3SS proteins are similar between different organisms 
(20). Two possible modes of targeting the needle apparatus directly could be protein-protein 
interactions within each component parts such as the needle monomer interactions or 
interactions between subsections such as the tip-translocon interaction (Figure 1).
Salmonella contains genetic loci that encode three T3SS operons with distinct functions. The 
Salmonella pathogenicity island-1 (SPI-1) encoded T3SS is the most studied and functions 
primarily in the initial invasion of non-phagocytic cells (33, 34). The SPI-2 T3SS is involved 
in the maintenance of Salmonella containing vacuoles and bacterial replication within host 
cells, though it’s structure has not been as extensively characterized (35). In addition, there 
is a flagellar T3SS (24). Other T3SS families include the Ysc and Ysa T3SS of Yersinia and 
the Sct T3SS of Chlamydia (36). Since part of the T3SS needle apparatus is exposed to the 
extracellular environment prior to and during infection, disrupting its assembly is a potential 
target for developing inhibitors.
Chaperones and effectors
T3SS effectors have a wide range of functions within the host cell, but often involve 
manipulating host cell signaling, secretory trafficking, cytoskeletal dynamics, or the 
inflammatory response (23, 37). It has been shown that effectors work in concert for 
infection (38). Regardless, deletions of many effectors attenuate virulence so they are 
considered potential drug targets (39–41). While in the bacterial cytoplasm, effectors are 
often in complex with chaperone proteins that target them to the export apparatus and 
protect from aggregation (42, 43). Disrupting chaperone/effector interactions could prevent 
secretion of effector proteins. However, some effectors, such as YopE and SopE, have been 
shown to retain partial secretion even the absence of their chaperone binding domain (43, 
44). Therefore, disruption of the chaperone/effector interactions may not necessarily result 
in a decrease in infectivity.
T3SS gene transcription
As stated above, the T3SS is organized into genetic loci whose gene expression is highly 
regulated by various transcription factors. Transcriptional regulators of both SPI-1 (45) and 
SPI-2 (46) loci have been identified in Salmonella. T3SS transcriptional regulators have also 
been characterized in other bacteria, such as Pseudomonas (47), Yersinia (48) and Shigella 
(49). Deletions of various T3SS transcription factors lead to the disappearance of the needle 
apparatuses on the bacterial surface due to essential constituents not being expressed (50). 
For this reason, transcription factors are potential drug targets as well.
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Literature of T3SS inhibitors
Salicylidene acylhydrazides
Many different classes of structurally diverse small molecule compounds have been 
identified as inhibitors of the T3SS (Figure 2 and Table 1). The most well studied class of 
T3SS inhibitors is the salicylidene acylhydrazides (SAHs). One of the first reports comes 
from Kauppi et al. (51, 52) where they performed a whole-cell assay screen against T3SS 
gene expression using a reporter of the effector protein YopE fused with luciferase in 
Yersinia. Out of 9,400 compounds tested, a few compounds were identified, including 
SAHs. A disadvantage of the assay was that it was based on coupling between Yop effector 
expression and secretion of the negative regulator LcrQ, therefore it was unclear whether the 
compounds acted directly against the T3SS (51). A follow up study showed that their SAH 
compounds directly blocked effector secretion of the T3SS in a dose-dependent manner and 
they were suggested to act at the level of the T3SS machinery (52, 53). SAHs have been 
shown to broadly inhibit the T3SS of many bacteria genera, including Chlamydia (54–57), 
Shigella (58), Salmonella (59–63) and pathogenic E. coli (64–66). Notably, most SAHs have 
been shown to have no negative affect on bacterial growth (51, 55, 61). Interestingly, some 
SAHs derivatives inhibited bacterial motility by acting on the flagella (51, 59, 60), while 
others did not affect bacterial motility (64).
The specific targets within the T3SS itself of many SAHs remain unknown or ambiguous, 
though putative targets have been suggested. First, it has been suggested that these 
compounds target the formation or assembly of the SPI-1 needle apparatus directly (58). 
Veenendaal et al. (58) showed by electron microscopy that Shigella needles were reduced in 
number by ~40% and the distribution of observed needle lengths was altered by one 
compound. Martinez-Argudo et al. (59) isolated SAH resistant Salmonella strains with a 
mutation in FlhA, a flagellar inner membrane protein, suggesting the compounds target the 
conserved basal body. Second, it has been suggested that SAHs target transcription factors or 
induce changes in cellular metabolism that affect the T3SS (65, 66). Wang et al. used affinity 
chromatography of conjugated beads of SAHS against E. coli lysate and identified three 
specific binding partners involved in bacterial cellular metabolism, WrbA, Tpx and FolX, 
and speculated targeting these proteins result in changes in T3SS gene expression by altering 
cellular metabolism (66). Importantly, binding was observed between the SAHs and 
homologs of WrbA and Tpx from other T3SS containing bacterial pathogens such as 
Salmonella and Pseudomonas (66). Since then, the crystal structure of Tpx has been solved 
and models of its binding to SAHs have been described (67). Finally, it has been suggested 
SAHs interfere with the T3SS through indirect methods, such as altering iron availability 
due to chelation (61, 63). In Salmonella and Chlamydia, the addition of exogenous iron 
attenuates the inhibitory effect of SAHs (55, 63, 68). Furthermore, a mutation in hemG, an 
enzyme involved with heme synthesized, conferred resistance to SAHs in Chlamydia (69). 
In addition, changes in gene expression of iron metabolism related genes has been reported 
in Salmonella, but not observed in E. coli, which suggests other mechanisms are at work 
(63, 65). Recently, a gallium(III)–salicylidene acylhydrazide complex has been shown to 
disrupt secretion and expression of T3SS proteins in addition to inhibiting biofilm formation 
in Pseudomonas (70). The current data on SAHs suggest they target the T3SS through 
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multiple mechanisms or that different SAH derivatives inhibit the system by different 
mechanisms.
Thiazolidinones
Another well studied class of T3SS inhibitors is the thiazolidinones. Felise et al. (71) 
identified thiazolidinone from a whole-cell screen assay in Salmonella against protein 
secretion using a reporter construct of the effector SipA fused to the Yersinia phospholipase 
YplA. Cleavage of a supplied substrate, PED6, by the reporter construct resulted in 
measurable fluorescence, which was proportional to the amount of the secreted SipA (71). 
Out of 92,000 screened compounds, a 2-imino-5-arylidene thiazolidinone was identified as a 
promising candidate, as it did not affect bacterial growth or T3SS transcription, and 
therefore was suggested to target formation or assembly of the needle apparatus (71). The 
compound was additionally shown to inhibit the T3SS of Yersinia, as well as the type II 
secretion system in Pseudomonas and the type IV pili secretion system of Francisella, 
though it did not target the flagellar-specific T3SS (71). Because of the broad range of 
action, it was hypothesized that the thiazolidinones target the conserved outer membrane 
Secretin protein. A follow up study showed that thiazolidinone dimers inhibited the T3SS 
more potently and it was suggested that the compounds act along a large oligomeric protein-
protein interaction surface (72).
Other classes of T3SS inhibitors
Many other chemically and structurally diverse classes of chemical inhibitors that affect the 
T3SS have been identified (Figure 2). Although the specific targets within the T3SS for most 
of these inhibitors have not been elucidated, the putative targets of a few compounds have 
been hypothesized. Yop secretion was inhibited by 2,2′-thiobis-(4-methylphenol) through an 
interaction with the minor translocon protein YopD of Yersinia (73). Unfortunately, this 
compound was shown to be toxic to eukaryotic cells and requires structural modification to 
be considered a suitable drug candidate (73). Mutations in the needle protein PscF of 
Pseudomonas conferred resistance against phenoxyacetamide inhibitors, suggesting PscF as 
their molecular target (74, 75). However, no biochemical binding assays showing a direct 
interaction between the two have been reported. Benzimidazoles have been shown to target 
the T3SS through inhibition of DNA binding by transcription factors such as LcrF in 
Yersinia (76, 77) and the Pseudomonas homolog ExsA (78). Similarly, 1-butyl-4-
nitromethyl-3-quinolin-2-yl-4H-quinoline inhibited the DNA binding of the Shigella 
transcription factor VirF, which controls transcription of Shigella T3SS genes (79). A variety 
of compounds have been shown to inhibit ATPases, such as YscN in Yersinia and its 
homolog BsaS in Burkholderia (80). Further, omeprazole inhibited the ATPase of the SPI-2 
T3SS of Salmonella, possibly through regulation of nitric oxide production (81). 
Pseudolipasin A inhibited phospholipase A2 activity of the Pseudomonas effector ExoU 
(82).
There are many small molecule inhibitors without known specific targets within the T3SS as 
shown in Table 1. A screen in Yersinia by Harmon et al. (83) identified various chemically 
diverse hydrophobic compounds that inhibited translocation of effectors into eukayrotic 
cells, but not in vitro secretion or expression, suggesting they disrupted the formation of a 
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functional translocon or that they inhibited interaction with the host cell. Various compounds 
showing inhibition of T3SS-mediated hemolysis, such as aurodox and the gaudinomines, 
have also been identified (84, 85). Other compounds, such as salicylanilides, 
salicylideneanilines, sulfonylaminobenzanilides, cytosporone B, and citrus flavonoids are 
hypothesized to broadly inhibit T3SS gene transcription through unknown mechanisms (53, 
64, 86–88).
Non-small molecule inhibitors of T3SS
Non-small molecule inhibitors of T3SS have been reported. These include polymers, 
proteins and polypeptide mimics. Ohgita et al. (89) reported that the proton-motive force 
dependent rotation of the Pseudomonas T3SS was inhibited by the addition of the viscous 
polymer polyethylene glycol (PEG) 8000 and this was hypothesized to occur by the 
resistance of physical rotation due to solution viscosity. This hypothesis was further 
supported by a follow up study showing that other viscous polymers, such as alginate and 
mucin, inhibited T3SS rotation while low viscosity polymers such as PEG200 do not (90). 
PEG derivatives are commonly used excipients in drug formulations (91) and because these 
experiments showed a direct correlation between the rotation of the T3SS needle apparatus 
and secretion of effectors, the addition of viscous polymers such as PEG as excipients to 
future antivirulence drug formulations is of interest (90, 91).
Proteins and polypeptides have also been reported as inhibitors of T3SS. For example, the 
glycoprotein Lactoferrin has been shown to decrease virulence of Salmonella, Shigella and 
E. coli by targeting the T3SS (92–95). In Shigella, Lactoferrin induced the loss and 
degradation of the translocon proteins IpaB and IpaC at the bacterial surface (94). Similarly, 
Lactoferrin caused the loss and degradation of the E. coli tip and translocon proteins (EspA, 
EspB and EspD) at the bacterial surface (92, 93, 96). Lactoferrin-mediated inhibition of the 
T3SS is thought to occur through two mechanisms. First, its ability to bind 
lipopolysaccharide on the bacterial surface is thought to cause instability of virulence 
proteins at the bacterial surface by disrupting essential protein-protein interactions (97). 
Second, the degradation of T3SS proteins occurs via the intrinsic serine protease activity of 
Lactoferrins (97). Additionally, Lactoferrin inhibits infection and has a bacteriostatic effect 
due to its ability to sequester iron, which is an essential micronutrient needed by many 
bacterial pathogens (97).
Polypeptide mimics targeting T3SS components have also been described. In Chlamydia, a 
28 amino acid polypeptide mimic targeting the CdsN ATPase via its interaction with the 
putative inner membrane-tethering protein CdsL inhibited bacterial invasion of eukaryotic 
host cells (98). In Salmonella, Hayward et al. (99) showed that a polypeptide derived from 
the C-terminus of the translocon protein SipB was shown to be a potent inhibitor of the 
membrane fusion activity of both wild-type SipB and the Shigella homolog IpaB in vitro. 
This polypeptide mimic also blocked the entry of Salmonella and Shigella into cultured 
eukaryotic cells (99). Finally, coiled-coiled peptides designed against the EPEC tip protein 
EspA inhibited T3SS-mediated hemolysis, EspA polymerization and secretion of effector 
proteins (100).
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Small molecules that bind T3SS proteins
Biologically relevant small molecules interact with structural and effector proteins of the 
T3SS and could potentially be used as scaffolds for drug design. These small molecules 
include sterols and lipids. Bile salts in the intestines of hosts are thought to act as 
environmental sensors for infection by Salmonella and Shigella (101). In Shigella, bile salts 
increase invasiveness to epithelial cells (102), while in Salmonella bile salts decrease 
invasiveness (103). Because the tip protein is assembled on the needle at the bacterial 
surface prior to host cell contact, it has been suggested to function as a sensor for the host 
environment by interacting with bile salts (101). NMR titrations suggested different 
interaction sites for bile salts such as deoxycholate and chenodeoxycholate on the 
Salmonella SipD and the Shigella IpaD tip proteins (104, 105). This is further supported by 
differences in the binding of deoxycholate in co-crystal structures with SipD (106) or IpaD 
(107). Interestingly, binding of bile salts was reported to induce a conformation change in 
IpaD, but not SipD (107), which possibly explains the difference in the responses observed 
between Salmonella and Shigella in the presence of bile salts.
The translocon proteins interact with sterols, for example, the Shigella IpaB translocon 
protein interacts with cholesterol and sphingolipids on host cell lipid rafts to mediate 
infection (108, 109). Binding of IpaB to sterol was proposed to cause the disorganization of 
the Golgi and other recycling networks by altering the distribution of cholesterol on the cell 
membrane and the sorting of the eukaryotic cell surface that promoted bacterial uptake 
(110). Interaction of cholesterol with homologous translocon proteins in other bacteria such 
as the Salmonella SipB and the Pseudomonas PopB/PopD proteins is required for infection 
(111, 112). Data also suggests interaction of translocon proteins with cholesterol is essential 
after initial infection. For example, the T3SS effectors IcsB from Shigella and BopA from 
Burkholderia bound to cholesterol leading to evasion of autophagy in host cells (113). In 
Salmonella, the SPI-2 effector SseJ caused esterification of cholesterol to maintain the 
Salmonella containing vacuole (114). Currently, a detailed mechanism of the molecular 
interactions of T3SS proteins with cholesterol or sphingolipids and their role in pathogenesis 
remain to be worked out.
Future Directions
Identification of T3SS targets
Drug discovery and development of small molecule inhibitors is lengthy and costly, with a 
potential drug candidate taking an average of over 10 years and costing millions of dollars to 
reach the market as an approved drug. The process often begins with a high throughput 
screen to identify potential hits. This is followed by target identification and validation, often 
in parallel with structure activity relationships to identify the most potent lead compound. 
Next, in vivo animal models are tested. If successful, pharmacokinetics and dynamics are 
analyzed and product is formulated as needed. Finally, clinical trials are performed.
The most pressing concern in the field is the identification and characterization of specific 
targets within the many protein components of the T3SS. Even with the most well studied 
classes of inhibitors, SAHs and thiazolidinones, the specific T3SS targets remain unknown 
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or ambiguous. This is likely due to the fact that most high throughout screens utilized assays 
that broadly monitored the secretion of effectors or gene transcription rather than using a 
targeted approach, such as a specific protein-protein interaction involved in the assembly of 
the T3SS needle apparatus. In addition, derivatives within a class of T3SS inhibitors have 
unique chemical structure that could potentially interact with non-T3SS targets in other 
organisms leading to differences in potency or mechanisms of action. This could explain the 
complex nature of the results observed in the literature of SAHs. A targeted and more 
specific approach for future high throughout screens could help solve this problem. Many 
binding assays have been developed to monitor protein-protein interactions of the structural 
proteins of the T3SS needle apparatus that could be adapted for drug screening. For 
example, fluorescence polarization and FRET assays show binding of the tip and translocon 
protein in Shigella (115) and NMR spectroscopy showed binding of the tip and needle 
protein in Salmonella (116).
SAR design
Structure-activity relationships (SAR) provide a direct link between the chemical structure 
of a molecule and its observed activity to create a potent lead compound. The identification 
of a target facilitates SAR studies especially when the mechanism of interaction is known, 
although they can be performed in the absence of a target (117). SAR studies have been 
initiated for a few T3SS inhibitor classes and extensively with SAHs. The data from SAR 
analysis of SAHs is complex and difficult to interpret. The salicylic phenol group is 
necessary for inhibiting activity, but substitutions in other positions are generally tolerable 
(52, 118). SAR based optimization of future SAHs compounds could be complicated if they 
target T3SS through multiple mechanisms as suggested in the literature (52, 118). SAR data 
on other classes of small molecule inhibitors of T3SS are available as well. Thiazolidinone 
analogs show sensitivity against substitutions at the imino N-2, amido N-3, and 5-arylidene 
groups and SAR analysis led to the identification of a more soluble derivative (71). 
Hydrophobicity and lipophilicity were shown to be important factors for inhibition of the 
T3SS by sulfonylaminobenzanilides (53). Cytosporone derivatives with extensive carbon 
chains containing a phenyl acetic acetate ester group were most potent (86). Derivatives of 
8-hydroxyquinoline required a fused pyridine ring and an aromatic hydroxyl group for 
inhibition of T3SS function (119). Benzimidazoles are sensitive to substitutions in the linker 
ringer and the middle phenyl ring (76). Finally, phenoxyacetamides were sensitive to 
changes on the A ring (where 2,4-dichlorophenyl is preferred) and their stereocenter was 
critical for T3SS inhibition and SAR analysis led to the identification of an 8-fold more 
potent compound than found in initial screens (74, 75).
Animal models, pharmacokinetics and formulation
Preliminary studies using animal models have shown the effectiveness of different T3SS 
inhibitors against infection in vivo and validated the approach of targeting T3SS (61, 77, 84, 
120). However, evaluation of pharmacokinetic parameters and formulation of potential drug 
molecule for delivery into host organisms is an essential step of drug discovery. Challenges 
with small molecule drug development include efflux, metabolism and membrane 
permeability. Notably, most of the literature describes relatively small and hydrophobic 
compounds that were identified through whole-cell screening, and therefore these 
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compounds are likely to be able to pass through cellular membranes. A study examined the 
pharmacokinetics of SAHs in a mouse model (120). Many compounds were shown to have a 
short half-life, suggesting rapid metabolism or clearance, as well as problems with 
compound stability and solubility (120). Attempts at formulation with the non-ionic 
surfactant Poloxamer 407 and the polysaccharide (2-hydroxypropyl)-β-cyclodextrin (120, 
121) were unsuccessful in improving efficacy. The ability of academia and the 
pharmaceutical industry to work together will speed the entry of new drugs into the pipeline 
by allowing for more extensive SAR optimization, pharmacokinetic analysis, formulation 
and in vivo testing of small molecule compounds (122).
Conclusions
The clinical application of small molecule inhibitors of bacterial virulence as anti-infectives 
remains to be exploited. Small molecule T3SS inhibitors that have been identified could be 
used to treat bacterial infection on their own because most of them are non-toxic to 
eukaryotic cells while still preventing secretion of effector proteins. Anti-infectives will not 
inhibit bacterial proliferation, thus bacteria must be cleared by other means such as the host 
immune system. These drugs may lead to increased immune cell memory. It is also possible 
that antivirulence drugs will need to be used in combination with other antibiotics for 
clearance. The discovery and validity of many classes of small molecule inhibitors targeting 
different aspects of the type III secretion systems of Gram-negative bacteria suggest that it is 
a promising approach that will applicable to clinical settings in the future.
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Potential Targeting Strategies for T3SS Inhibitors. Cartoon showing potential targeting 
strategies of the T3SS, including the T3SS apparatus, effector proteins and transcription 
factors.
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Structure of T3SS Inhibitors. Structure of the classes of T3SS inhibitors outlined in Table 1. 
Structures were made using ChemBioDraw 13.0.
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Table 1




Organism T3SS Target Reference
(−)-Hopeaphenol 4 Yersinia, Pseudomonas, Chlamydia ? (123)




2-imino-5-arylidene thiazolidinone 13 Yersinia, Salmonella also inhibits 
T2S of Pseudomonas and T4-Pilli 
Secretion of Francisella
Secretin? (71, 72, 124)
2,2′-thiobis-(4-methylphenol) 14 Yersinia
Pseudomonas
YopD / translocon (73)
8-hydroxyquinolines [INP1750] 1 Yersinia, Chlamydia ? (119)
Aurodox 5 EPEC, Citrobacter ? (84)








Caminoside A-D 7 EPEC ? (125, 126)
Citrus Flavonoids 11 Vibrio ? (87)
Cytosporone B 8 Salmonella ? (86)
Gaudinomine A-D 12 EPEC ? (85)





Phenoxyacetamide 16 Pseudomonas PscF / needle 
protein
(74, 75)
Piericidin A1 3 Yersinia ? (127)
Pseudoceramine 18 Yersinia ? (128)
Pseudolipasin A 9 Pseudomonas ExoU / effector (10)
Salicylanilide 20 Yersinia ? (51, 88, 129)
Salicylidene
Acylhydrazide
2 Chlamydia HemG / heme 
metabolism
(54–57, 120, 130)
Yersinia ? (51, 52)
Shigella needle assembly? (58)

















Organism T3SS Target Reference




EPEC ?, possibly due to 
non-T3SS cell 
metabolism 
enzymes, such as 
WrbA/Tpx/FolX
(64–66)
Salicylideneaniline 19 Yersinia, EPEC ? (64)
Sulfonylaminobenzanilide 17 Yersinia ? (51, 53)
Thiohydrazones of Thiohydrazide 6 Chlamydia ? (131)
Various Compounds not shown Yersinia, EPEC ? (132, 133)
Various Compounds not shown Yersinia ? (83)





Viscous Polymers [PEG8000 / Alginate / Mucin] not shown Pseudomonas inhibits T3SS 
apparatus rotation
(90)




Polypeptide Mimics not shown Salmonella/Shigella SipB, IpaB / 
Translocon
(134)
EPEC CdsN ATPase (98)
EspA / tip (100)
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